Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer
- 13 January 2005
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in World Journal of Urology
- Vol. 23 (1), 47-49
- https://doi.org/10.1007/s00345-004-0475-z
Abstract
Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express unique proteins which serve as highly specific targets. APC8015 (Provenge) is one such investigational therapeutic vaccine that uses autologous antigen presenting cells (APCs) loaded with a recombinant fusion protein of prostatic acid phosphatase linked to a molecule that specifically targets a receptor expressed on the surface of human APCs. Clinical trial outcomes have demonstrated activity in patients with androgen independent prostate cancer.Keywords
This publication has 7 references indexed in Scilit:
- Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 toleranceNature Immunology, 2004
- Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate CancerJournal of Clinical Oncology, 2003
- Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer.2003
- A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate CarcinomaJNCI Journal of the National Cancer Institute, 2002
- Identification of T helper epitopes from prostatic acid phosphatase.2001
- Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.2001
- A fresh look at tumor immunosurveillance and immunotherapyNature Immunology, 2001